Dasatinib, a targeted therapy drug used in the treatment of specific leukemias, represents a significant advancement in cancer treatment. Its complex molecular structure is built through intricate chemical synthesis pathways, where specific intermediates play crucial roles. Among these, 3-Ethoxyacryloyl chloride (CAS: 6191-99-7) stands out as a pivotal compound.

The synthesis of Dasatinib involves several critical chemical transformations, and 3-Ethoxyacryloyl chloride serves as a foundational building block. Its chemical structure, featuring an acryloyl chloride moiety with an ethoxy group, provides the necessary reactivity for forming key bonds within the Dasatinib molecule. This intermediate is essential for constructing the thiazole carboxamide core, which is integral to Dasatinib's pharmacological activity.

Researchers in medicinal chemistry and process development leverage the chemical properties of 3-Ethoxyacryloyl chloride to design efficient and scalable synthetic routes. The compound's relatively high purity, typically above 98%, minimizes the introduction of impurities that could complicate downstream purification steps or affect the final API's quality.

The use of 3-Ethoxyacryloyl chloride in the synthesis of Dasatinib underscores the importance of specialized fine chemicals in the pharmaceutical industry. Its availability, coupled with detailed technical specifications and reliable sourcing, empowers chemists to develop robust manufacturing processes.

Understanding the chemical transformations involving 3-Ethoxyacryloyl chloride provides valuable insight into the overall efficiency and feasibility of Dasatinib production. As the demand for targeted cancer therapies continues to grow, the role of such key intermediates in ensuring timely and quality-assured drug manufacturing will remain indispensable.